Dreamgenics is a biotechnology company that develops its activity in the field of omics technologies and bioinformatics. We perform bioinformatic analysis of Next-generation Sequencing (NGS) data using in-house developed bioinformatics tools, which gives us an important competitive advantage over other companies.
We also carry out analysis of multiplexed protein and genes panels using Luminex xMAP® and xTAG® technologies that cover more than 600 proteins and 17.000 genes in humans and other species. These technologies allow the study of biomarkers in cancer, cardiovascular diseases, immunology, neuroscience, endocrinology, etc. Panels can be configured by clients according to the particular needs of their line of research.
Globally, our objective as a biotechnology company is to help clinicians and researchers to understand the molecular basis of diseases and thus help these patients to benefit from the development and implementation of Precision Medicine in clinical practice.
2011: Dreamgenics emerges as a spinoff of the University of Oviedo.
2013: Development of Genome one software for bioinformatics analysis of NGS data.
2014-2020: Development of gene panels for different pathologies.
2015: New investors join us and boost our job.
2018: Development of Genome one Reports web solution for visualization and review of results.
2020: Opening of new facilities including a Molecular Biology Laboratory.
2021: Acquisition of MAGPIX equipment (Luminex).
- Area of Activity
- Technology transfer
- Research services and supplies
- Science - Technology parks
- Internet and information technologies
- Manufacture of biotech equipment
- Software development
- Biotechnology kits
- Research Centers
- Cellular and molecular biology
- Company type
- Services and consulting for biotech sector
- Public and Private Organizations - Non Profit Centers - Medical Research Facilities
- Technology Services
- Industrial Biotechnology - Manufacturers
- Health Biotechnology
Finlandia, Nº2 1º
Oviedo , Asturias 33010, ES
P: +34 985 088 180
Carlos Martínez / Chief Executive Officer •Roberto Álvarez / Chief Technology Officer
•Laura González-Silva / Scientific Manager
•Patricia Cueto / Bioinformatics Scientist & Data Analyst
•Claudia García / Bioinformatics Scientist
•Sara Bonilla / Bioinformatics Scientist
•Alicia Gómez / Bioinformatics Scientist
•Daniel Giménez / Software Developer
•Javier Rodríguez / Software Developer
•Érica Morán / Head of Molecular Biology Lab & Scientific Commercial Manager
•Virginia Merino / Laboratory Technician
•Arancha Cueto / Laboratory Technician
•Javier Riera / Key Account Executive
•Cristina Sainz / Administrative and Financial Manager & Quality Manager
•Patricia Maroño / Marketing Assistant
We are experts in bioinformatics analysis of NGS data, including whole genome sequencing (WES), whole exome sequencing (WES), trio exome, gene panels, RNA-seq, metagenomics, etc.
•Genome one software
•Genome one Reports Viewer
All analyses performed with Genome one comply with the necessary requirements regarding CE-IVD marking and the UNE EN ISO 13485:2016 standard.
•Multiplexed gene panels
•Multiplexed protein panels
We perform bioinformatics analysis of NGS data using proprietary bioinformatics tools. We also deliver the results through Genome one Reports, an intuitive web platform that allows interactive visualisation and review of the results, as well as exporting all tables and figures so that they can be used in scientific publications.
In addition, we carry out the analysis of multiplexed gene and protein panels to study biomarkers of cancer, cardiovascular diseases, immunology, neurology, metabolism and endocrinology, etc. in samples of serum, plasma, urine, extravascular fluids, biopsies and cell cultures, among others.
Dreamgenics' customers can be divided into two groups: on the one hand, there are researchers and clinicians carrying out research projects involving massive sequencing techniques and therefore need a bioinformatics analysis service.
On the other hand, there are companies that carry out routine genomic analysis for diagnostic purposes (genomes, exomes, trio exome and gene panels) and need a partner to carry out the bioinformatics analysis of these samples.